A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-COHORT STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF PF-07328948 IN ADULTS WITH RENAL IMPAIRMENT AND HEALTHY ADULT PARTICIPANTS WITH NORMAL RENAL FUNCTION
Latest Information Update: 06 Jan 2026
At a glance
- Drugs PF 07328948 (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 06 Jan 2026 New trial record